Obatoclax

Drug Profile

Obatoclax

Alternative Names: CEP-41601; GX 15-070; GX15-070MS; Obatoclax mesylate

Latest Information Update: 09 Feb 2015

Price : $50

At a glance

  • Originator Gemin X Biotechnologies
  • Class Antineoplastics; Pyrroles; Small molecules
  • Mechanism of Action Apoptosis stimulants; Autophagy stimulants; Proto-oncogene protein c-bcl-2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Myelodysplastic syndromes; Chronic lymphocytic leukaemia; Myelofibrosis
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Chronic lymphocytic leukaemia; Follicular lymphoma; Mantle-cell lymphoma; Multiple myeloma; Myelodysplastic syndromes; Myelofibrosis; Non-small cell lung cancer; Small cell lung cancer; Systemic mastocytosis

Most Recent Events

  • 31 Dec 2013 Discontinued - Phase-II for Small cell lung cancer (Combination therapy, First-line therapy) in USA, Canada, United Kingdom, Bulgaria, Romania, Poland, Czech Republic, Hungary, Serbia and India (IV)
  • 31 Dec 2013 Discontinued - Phase-I for Multiple myeloma in USA (IV)
  • 31 Dec 2013 Discontinued - Phase-I/II for Mantle cell lymphoma (Combination therapy, Second-line therapy or greater) in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top